Document is current
Any future updates will be listed below
-
Authors
Pruneda, Jonathan N. https://orcid.org/0000-0002-0304-4418
Damgaard, Rune Busk https://orcid.org/0000-0002-1709-6534
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF19OC0054248)
Det Frie Forskningsråd (3101-00245B)
Kræftens Bekæmpelse (R352-A20458)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142486)
- License Information
-
More Information
Article History
Received: 12 November 2025
Revised: 8 December 2025
Accepted: 21 January 2026
First Online: 29 January 2026
Competing interests
: RBD is a scientific advisor for Flindr Therapeutics. JNP has no competing interests.
